JP2018104450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018104450A5 JP2018104450A5 JP2018024505A JP2018024505A JP2018104450A5 JP 2018104450 A5 JP2018104450 A5 JP 2018104450A5 JP 2018024505 A JP2018024505 A JP 2018024505A JP 2018024505 A JP2018024505 A JP 2018024505A JP 2018104450 A5 JP2018104450 A5 JP 2018104450A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- halo
- membered
- alkylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474821P | 2011-04-13 | 2011-04-13 | |
| US61/474,821 | 2011-04-13 | ||
| US201161499595P | 2011-06-21 | 2011-06-21 | |
| US61/499,595 | 2011-06-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016050059A Division JP2016147886A (ja) | 2011-04-13 | 2016-03-14 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018181993A Division JP2019014732A (ja) | 2011-04-13 | 2018-09-27 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018104450A JP2018104450A (ja) | 2018-07-05 |
| JP2018104450A5 true JP2018104450A5 (enExample) | 2018-11-08 |
| JP6778226B2 JP6778226B2 (ja) | 2020-10-28 |
Family
ID=46045109
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505372A Active JP5933686B2 (ja) | 2011-04-13 | 2012-04-13 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2016050059A Withdrawn JP2016147886A (ja) | 2011-04-13 | 2016-03-14 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2018024505A Active JP6778226B2 (ja) | 2011-04-13 | 2018-02-14 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2018181993A Pending JP2019014732A (ja) | 2011-04-13 | 2018-09-27 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2020197115A Withdrawn JP2021042243A (ja) | 2011-04-13 | 2020-11-27 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2022181039A Pending JP2023011933A (ja) | 2011-04-13 | 2022-11-11 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505372A Active JP5933686B2 (ja) | 2011-04-13 | 2012-04-13 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2016050059A Withdrawn JP2016147886A (ja) | 2011-04-13 | 2016-03-14 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018181993A Pending JP2019014732A (ja) | 2011-04-13 | 2018-09-27 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2020197115A Withdrawn JP2021042243A (ja) | 2011-04-13 | 2020-11-27 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
| JP2022181039A Pending JP2023011933A (ja) | 2011-04-13 | 2022-11-11 | アリール置換またはヘテロアリール置換ベンゼン化合物 |
Country Status (35)
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| KR102453519B1 (ko) * | 2012-03-12 | 2022-10-11 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| HUE045353T2 (hu) | 2012-04-13 | 2019-12-30 | Epizyme Inc | N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)-metil)-5-(etil-(tetrahidro-2H-pirán-4-il) -amino)-4-metil-4'-(morfolino-metil)-[1,1'-bifenil]-3-karboxamid-hidrobromid a hematológiai rendszer egy sejtszaporodásos rendellenességének kezelésében való alkalmazásra |
| NZ729643A (en) * | 2012-04-13 | 2018-02-23 | Epizyme Inc | Combination therapy for treating cancer |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2884848C (en) * | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| CA2887562C (en) | 2012-10-15 | 2021-01-12 | Epizyme, Inc. | Substituted benzene compounds |
| MX376008B (es) * | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| CN104968646B (zh) | 2012-12-13 | 2017-09-05 | 葛兰素史密斯克莱有限责任公司 | Zeste同源物增强子2的抑制剂 |
| EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| EP2935214B1 (en) * | 2012-12-21 | 2019-02-20 | Epizyme, Inc. | 1,4-pyridone compounds |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CN105102446B (zh) * | 2013-02-11 | 2018-01-23 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物及用途 |
| KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| BR112015022604A2 (pt) | 2013-03-14 | 2017-10-24 | Genentech Inc | usos de um modulador de modificador de cromatina e um antagonista de egfr |
| US8952026B2 (en) | 2013-03-14 | 2015-02-10 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9776972B2 (en) | 2013-03-14 | 2017-10-03 | Epizyme Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2970281A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZOL COMPOUNDS |
| ES2717680T3 (es) | 2013-04-30 | 2019-06-24 | Glaxosmithkline Ip No 2 Ltd | Potenciador de inhibidores del homólogo de Zeste 2 |
| WO2014195919A1 (en) * | 2013-06-06 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2016523955A (ja) * | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| US9822103B2 (en) | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| ES2863996T3 (es) * | 2013-12-06 | 2021-10-13 | Epizyme Inc | Terapia de combinación para el tratamiento del cáncer |
| CN105037360B (zh) * | 2014-04-28 | 2016-08-17 | 四川大学 | 吡啶酮衍生物及其制备方法和用途 |
| CA2952074C (en) | 2014-06-17 | 2022-08-30 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| TN2016000529A1 (en) | 2014-06-17 | 2018-04-04 | Pfizer | Substituted dihydroisoquinolinone compounds |
| WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| CN107001385B (zh) | 2014-08-21 | 2020-03-13 | 勃林格殷格翰国际有限公司 | 作为mdm2-p53抑制剂的螺-[3h-吲哚-3，2’-吡咯烷]-2(1h)-酮化合物及其衍生物 |
| CN112168967A (zh) | 2014-10-16 | 2021-01-05 | Epizyme股份有限公司 | 治疗癌症的方法 |
| CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| EP3214935A4 (en) | 2014-11-06 | 2018-08-29 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| IL296080B2 (en) | 2014-11-17 | 2023-12-01 | Eisai R&D Man Co Ltd | Method for treating cancer |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| AU2016252546A1 (en) | 2015-04-20 | 2017-11-02 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN107635965A (zh) | 2015-06-10 | 2018-01-26 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| EA201890567A1 (ru) | 2015-08-24 | 2018-08-31 | Эпизайм, Инк. | Способ лечения рака |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| CN108699046A (zh) * | 2015-10-06 | 2018-10-23 | Epizyme股份有限公司 | 用ezh2抑制剂治疗成神经管细胞瘤的方法 |
| CN119569740A (zh) | 2015-10-09 | 2025-03-07 | 勃林格殷格翰国际有限公司 | 作为mdm2-p53抑制剂的化合物及其衍生物 |
| WO2017079757A1 (en) * | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| EP3378859B1 (en) | 2015-11-19 | 2019-10-30 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
| CN105440023A (zh) * | 2015-12-10 | 2016-03-30 | 江苏理工学院 | Epz-6438的合成方法 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| JP2019503391A (ja) * | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| WO2017174023A1 (zh) * | 2016-04-08 | 2017-10-12 | 南京明德新药研发股份有限公司 | 作为ezh2抑制剂的联苯化合物 |
| EP3445365A4 (en) * | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
| WO2017192290A1 (en) | 2016-05-04 | 2017-11-09 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs |
| CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| US11786533B2 (en) * | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| JP7208898B2 (ja) | 2016-12-02 | 2023-01-19 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CN108314677B (zh) | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| AU2018210099A1 (en) | 2017-01-19 | 2019-08-15 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11672800B2 (en) * | 2017-04-21 | 2023-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| EP3626715A4 (en) | 2017-05-18 | 2021-03-24 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| US20230201212A1 (en) | 2017-06-13 | 2023-06-29 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3082287C (en) | 2017-11-14 | 2023-02-28 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CN108640842B (zh) * | 2018-04-04 | 2021-06-04 | 大连九信精细化工有限公司 | 一种2-溴-5-氟硝基苯的合成方法 |
| JP7461304B2 (ja) | 2018-06-07 | 2024-04-03 | メルク・シャープ・アンド・ドーム・エルエルシー | スガマデクスの製造方法 |
| CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
| EP3831822A4 (en) * | 2018-07-27 | 2022-03-23 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | POLYSUBSTITUTED BENZENE COMPOUND AND METHOD FOR PREPARING IT AND ITS USE |
| KR102689665B1 (ko) | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| US12473298B2 (en) | 2019-03-25 | 2025-11-18 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Amide compounds, preparation method therefor, and use thereof in the medical field |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| EP3965824B1 (en) | 2019-05-06 | 2025-01-08 | Icahn School of Medicine at Mount Sinai | Heterobifunctional compounds as degraders of hpk1 |
| US12252493B2 (en) | 2019-06-05 | 2025-03-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| MA56661B1 (fr) | 2019-07-24 | 2025-01-31 | Constellation Pharmaceuticals, Inc. | Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide |
| EP4017527A1 (en) | 2019-08-22 | 2022-06-29 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| CN115551842B (zh) * | 2020-06-08 | 2024-04-23 | 南京明德新药研发有限公司 | 联苯类化合物 |
| EP4556479A1 (en) | 2020-08-13 | 2025-05-21 | Hanmi Pharmaceutical Co., Ltd. | Novel dioxoloisoquinolinone derivatives and use thereof |
| KR20230088422A (ko) * | 2020-10-13 | 2023-06-19 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 다중치환된 벤젠 고리 화합물 말레이트의 결정형, 이의 제조 방법 및 이의 용도 |
| CN114907300B (zh) * | 2021-02-08 | 2024-05-28 | 上海医药工业研究院 | 他泽司他关键中间体的制备方法及其中间体 |
| CN114907299B (zh) * | 2021-02-08 | 2024-06-25 | 上海医药工业研究院 | 他泽司他关键中间体的盐型、其制备方法及其中间体 |
| CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
| CN113527275A (zh) * | 2021-07-20 | 2021-10-22 | 成都师范学院 | 一种sklb1039化合物及其制备方法和应用 |
| CN113582863B (zh) * | 2021-08-19 | 2023-05-26 | 沈阳农业大学 | 一种氨乙基联苯类化合物及其制备方法和用途 |
| KR20230081459A (ko) | 2021-11-30 | 2023-06-07 | 엘젠테라퓨틱스 주식회사 | 헤테로사이클릭이 치환된 신규한 3-페닐피리딘과 4-페닐피리딘 유도체 및 이의 용도 |
| US20250049802A1 (en) | 2021-12-14 | 2025-02-13 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| JP2025513620A (ja) | 2022-04-27 | 2025-04-24 | 第一三共株式会社 | 抗体－薬物コンジュゲートとｅｚｈ１阻害剤および／またはｅｚｈ２阻害剤との組合せ |
| AU2023292893A1 (en) | 2022-06-13 | 2025-01-02 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| CA3258412A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | HETEROBORCTIONAL BCL6 DEGRADING AGENTS 1,8-NAPHTHYRIDIN-2-ONE |
| CN115197202B (zh) * | 2022-07-15 | 2024-01-26 | 四川大学 | 一种ezh2共价抑制剂及其制备方法和应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| FI953968A7 (fi) | 1993-12-27 | 1995-10-19 | Eisai Co Ltd | Antraniiliset happojohdannaiset |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| CN1332722A (zh) | 1998-09-30 | 2002-01-23 | 宝洁公司 | 2－取代的酮酰胺 |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| US6977266B2 (en) * | 2000-12-28 | 2005-12-20 | Shionogi & Co., Ltd. | Pyridone derivatives having affinity for cannabinoid 2-type receptor |
| JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| ES2421511T3 (es) * | 2001-12-21 | 2013-09-03 | X Ceptor Therapeutics Inc | Moduladores de LXR |
| EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| EP2281564A3 (en) | 2002-12-27 | 2012-09-05 | Sucampo AG | Derivatives of prostaglandins for treating abdominal discomfort |
| ES2502490T3 (es) * | 2003-02-26 | 2014-10-03 | Sugen, Inc. | Compuestos aminoheteroarílicos como inhibidores de proteín quinasas |
| WO2005014599A1 (en) * | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| WO2004112719A2 (en) | 2003-06-19 | 2004-12-29 | Smithkline Beecham Corporation | Chemical compounds |
| US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| RU2356547C2 (ru) | 2003-08-26 | 2009-05-27 | Мерк ЭйчДиЭйСи Рисерч ЛЛС | Способы лечения рака с использованием ингибиторов hdac |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| US7897788B2 (en) | 2004-03-11 | 2011-03-01 | Actelion Pharmaceutical Ltd. | Indol-1-yl-acetic acid derivatives |
| CN1286973C (zh) | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
| EP1765994B1 (en) | 2004-06-01 | 2009-11-18 | The University of North Carolina at Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ATE494548T1 (de) | 2005-06-02 | 2011-01-15 | Univ North Carolina | Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP2388258A1 (de) | 2005-10-19 | 2011-11-23 | Grünenthal GmbH | Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| KR20080057296A (ko) | 2005-10-21 | 2008-06-24 | 머크 앤드 캄파니 인코포레이티드 | 칼륨 채널 억제제 |
| JP5078901B2 (ja) | 2005-10-28 | 2012-11-21 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ＪｍｊＣドメインを含むタンパク質デメチラーゼ |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| KR20080110905A (ko) | 2006-05-15 | 2008-12-19 | 아이알엠 엘엘씨 | 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도 |
| WO2007136592A2 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents |
| JP2010505958A (ja) | 2006-10-10 | 2010-02-25 | バーンハム インスティトゥート フォー メディカル リサーチ | 神経防護作用組成物および方法 |
| EP2114898A2 (en) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008109534A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| US8110572B2 (en) | 2007-07-16 | 2012-02-07 | Abbott Laboratories | Inhibitors of protein kinases |
| AU2008319308B2 (en) * | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| EP2229391B1 (en) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| EP2235001B1 (en) | 2008-01-23 | 2014-12-24 | Bristol-Myers Squibb Company | Process for preparing pyridinone compounds |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| UY31982A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| WO2010017355A2 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| US20120208809A1 (en) * | 2009-03-24 | 2012-08-16 | Sanofi | 9h-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof |
| US20120065247A1 (en) | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| BR112012028556A2 (pt) * | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | Indóis |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| AU2011336272A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| KR102453519B1 (ko) | 2012-03-12 | 2022-10-11 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| NZ729643A (en) | 2012-04-13 | 2018-02-23 | Epizyme Inc | Combination therapy for treating cancer |
| HUE045353T2 (hu) | 2012-04-13 | 2019-12-30 | Epizyme Inc | N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)-metil)-5-(etil-(tetrahidro-2H-pirán-4-il) -amino)-4-metil-4'-(morfolino-metil)-[1,1'-bifenil]-3-karboxamid-hidrobromid a hematológiai rendszer egy sejtszaporodásos rendellenességének kezelésében való alkalmazásra |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| CA2887562C (en) | 2012-10-15 | 2021-01-12 | Epizyme, Inc. | Substituted benzene compounds |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| ES2863996T3 (es) | 2013-12-06 | 2021-10-13 | Epizyme Inc | Terapia de combinación para el tratamiento del cáncer |
| CA2952074C (en) | 2014-06-17 | 2022-08-30 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| CN112168967A (zh) | 2014-10-16 | 2021-01-05 | Epizyme股份有限公司 | 治疗癌症的方法 |
| IL296080B2 (en) | 2014-11-17 | 2023-12-01 | Eisai R&D Man Co Ltd | Method for treating cancer |
| AU2016252546A1 (en) | 2015-04-20 | 2017-11-02 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN107635965A (zh) | 2015-06-10 | 2018-01-26 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
| EA201890567A1 (ru) | 2015-08-24 | 2018-08-31 | Эпизайм, Инк. | Способ лечения рака |
| US20180296563A1 (en) | 2015-09-25 | 2018-10-18 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor |
| EP3674709A1 (en) | 2015-11-05 | 2020-07-01 | Epizyme Inc | Flow cytometry for monitoring histone h3 methylation status |
| AU2016365739A1 (en) | 2015-12-07 | 2018-06-07 | Epizyme, Inc. | Inhibitors of EZH2 and methods of use thereof |
| JP2019503391A (ja) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| JP2019508406A (ja) | 2016-02-08 | 2019-03-28 | エピザイム，インコーポレイティド | 癌を処置する方法 |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| JP7208898B2 (ja) | 2016-12-02 | 2023-01-19 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| AU2018217139A1 (en) | 2017-02-02 | 2019-08-22 | Epizyme, Inc. | Cancer treatment modalities |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| US20230201212A1 (en) | 2017-06-13 | 2023-06-29 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2020408395A1 (en) | 2019-12-20 | 2022-07-07 | Epizyme, Inc. | Crystalline hydrobromide salt of a EZH2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
| WO2021243060A1 (en) | 2020-05-28 | 2021-12-02 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
-
2011
- 2011-04-13 JO JOP/2018/0104A patent/JO3438B1/ar active
-
2012
- 2012-04-10 JO JOP/2012/0087A patent/JO3363B1/ar active
- 2012-04-12 TW TW101112994A patent/TWI529162B/zh active
- 2012-04-13 RU RU2013150345A patent/RU2632193C2/ru active
- 2012-04-13 SM SM20210503T patent/SMT202100503T1/it unknown
- 2012-04-13 NZ NZ616298A patent/NZ616298A/en unknown
- 2012-04-13 PL PL16172386T patent/PL3150580T3/pl unknown
- 2012-04-13 MY MYPI2013003694A patent/MY166171A/en unknown
- 2012-04-13 ES ES21175920T patent/ES2973868T3/es active Active
- 2012-04-13 RS RS20190065A patent/RS58226B1/sr unknown
- 2012-04-13 KR KR1020137029930A patent/KR101914321B1/ko active Active
- 2012-04-13 AU AU2012242595A patent/AU2012242595B2/en active Active
- 2012-04-13 EP EP23217912.7A patent/EP4360712A3/en active Pending
- 2012-04-13 SG SG2013075478A patent/SG194447A1/en unknown
- 2012-04-13 EP EP21175920.4A patent/EP3943485B1/en active Active
- 2012-04-13 SI SI201232058T patent/SI3943485T1/sl unknown
- 2012-04-13 CA CA2832843A patent/CA2832843C/en active Active
- 2012-04-13 ES ES18200713T patent/ES2886099T3/es active Active
- 2012-04-13 PL PL21175920.4T patent/PL3943485T3/pl unknown
- 2012-04-13 DK DK16172386.1T patent/DK3150580T3/en active
- 2012-04-13 LT LTEP18200713.8T patent/LT3486234T/lt unknown
- 2012-04-13 SI SI201231941T patent/SI3486234T1/sl unknown
- 2012-04-13 MX MX2013011921A patent/MX343685B/es active IP Right Grant
- 2012-04-13 FI FIEP21175920.4T patent/FI3943485T3/fi active
- 2012-04-13 HU HUE18200713A patent/HUE056552T2/hu unknown
- 2012-04-13 HU HUE21175920A patent/HUE066461T2/hu unknown
- 2012-04-13 EP EP16172386.1A patent/EP3150580B1/en active Active
- 2012-04-13 DK DK12719529.5T patent/DK2697199T3/en active
- 2012-04-13 BR BR112013026324-5A patent/BR112013026324B1/pt active IP Right Grant
- 2012-04-13 NZ NZ717119A patent/NZ717119A/en unknown
- 2012-04-13 KR KR1020207024969A patent/KR102308488B1/ko active Active
- 2012-04-13 KR KR1020197029487A patent/KR102154946B1/ko active Active
- 2012-04-13 KR KR1020197005890A patent/KR102032303B1/ko active Active
- 2012-04-13 JP JP2014505372A patent/JP5933686B2/ja active Active
- 2012-04-13 EP EP18200713.8A patent/EP3486234B1/en active Active
- 2012-04-13 KR KR1020217030083A patent/KR102566864B1/ko active Active
- 2012-04-13 LT LTEP12719529.5T patent/LT2697199T/lt unknown
- 2012-04-13 HU HUE16172386A patent/HUE042788T2/hu unknown
- 2012-04-13 PH PH1/2013/502118A patent/PH12013502118A1/en unknown
- 2012-04-13 HR HRP20161115TT patent/HRP20161115T1/hr unknown
- 2012-04-13 NZ NZ734744A patent/NZ734744A/en unknown
- 2012-04-13 CN CN201710425075.8A patent/CN107311921B/zh active Active
- 2012-04-13 RS RS20211082A patent/RS62279B1/sr unknown
- 2012-04-13 LT LTEP16172386.1T patent/LT3150580T/lt unknown
- 2012-04-13 KR KR1020187030566A patent/KR101955871B1/ko active Active
- 2012-04-13 SM SM20190050T patent/SMT201900050T1/it unknown
- 2012-04-13 PE PE2013002280A patent/PE20140863A1/es active IP Right Grant
- 2012-04-13 PL PL12719529.5T patent/PL2697199T3/pl unknown
- 2012-04-13 HR HRP20211297TT patent/HRP20211297T8/hr unknown
- 2012-04-13 PL PL18200713T patent/PL3486234T3/pl unknown
- 2012-04-13 US US13/447,007 patent/US8410088B2/en active Active
- 2012-04-13 HU HUE12719529A patent/HUE028837T2/en unknown
- 2012-04-13 EP EP12719529.5A patent/EP2697199B1/en active Active
- 2012-04-13 WO PCT/US2012/033648 patent/WO2012142504A1/en not_active Ceased
- 2012-04-13 ME MEP-2016-175A patent/ME02500B/me unknown
- 2012-04-13 SI SI201231505T patent/SI3150580T1/sl unknown
- 2012-04-13 KR KR1020257026777A patent/KR20250126865A/ko active Pending
- 2012-04-13 PT PT182007138T patent/PT3486234T/pt unknown
- 2012-04-13 ES ES16172386T patent/ES2706951T3/es active Active
- 2012-04-13 MX MX2016010614A patent/MX384521B/es unknown
- 2012-04-13 PT PT16172386T patent/PT3150580T/pt unknown
- 2012-04-13 AR ARP120101288A patent/AR086008A1/es active IP Right Grant
- 2012-04-13 LT LTEP21175920.4T patent/LT3943485T/lt unknown
- 2012-04-13 RS RS20160706A patent/RS55113B1/sr unknown
- 2012-04-13 SI SI201230695A patent/SI2697199T1/sl unknown
- 2012-04-13 DK DK18200713.8T patent/DK3486234T3/da active
- 2012-04-13 ES ES12719529.5T patent/ES2589555T3/es active Active
- 2012-04-13 CN CN201280029207.0A patent/CN104080769B/zh active Active
- 2012-04-13 BR BR122020006541-9A patent/BR122020006541B1/pt active IP Right Grant
- 2012-04-13 PT PT211759204T patent/PT3943485T/pt unknown
- 2012-04-13 DK DK21175920.4T patent/DK3943485T3/da active
- 2012-04-13 PH PH1/2016/502132A patent/PH12016502132B1/en unknown
- 2012-04-13 PT PT127195295T patent/PT2697199T/pt unknown
- 2012-04-13 KR KR1020237027131A patent/KR20230134128A/ko not_active Ceased
- 2012-04-13 CA CA3086473A patent/CA3086473A1/en active Pending
- 2012-12-20 US US13/722,807 patent/US8765732B2/en active Active
-
2013
- 2013-10-06 IL IL228745A patent/IL228745A/en active IP Right Grant
- 2013-10-09 ZA ZA2013/07539A patent/ZA201307539B/en unknown
- 2013-10-10 CL CL2013002898A patent/CL2013002898A1/es unknown
- 2013-10-11 MX MX2020012695A patent/MX2020012695A/es unknown
-
2014
- 2014-05-12 US US14/275,667 patent/US9090562B2/en active Active
-
2015
- 2015-06-17 US US14/742,481 patent/US9549931B2/en active Active
- 2015-10-06 US US14/876,658 patent/US9522152B2/en active Active
-
2016
- 2016-03-14 JP JP2016050059A patent/JP2016147886A/ja not_active Withdrawn
- 2016-09-07 CY CY20161100879T patent/CY1117986T1/el unknown
- 2016-09-08 SM SM201600308T patent/SMT201600308B/it unknown
- 2016-11-08 US US15/346,677 patent/US10155002B2/en active Active
- 2016-11-29 IL IL249273A patent/IL249273B/en active IP Right Grant
-
2017
- 2017-05-17 US US15/598,078 patent/US9855275B2/en active Active
- 2017-11-17 US US15/816,907 patent/US10420775B2/en active Active
-
2018
- 2018-02-14 JP JP2018024505A patent/JP6778226B2/ja active Active
- 2018-09-27 JP JP2018181993A patent/JP2019014732A/ja active Pending
-
2019
- 2019-01-11 HR HRP20190074TT patent/HRP20190074T1/hr unknown
- 2019-01-14 CY CY191100038T patent/CY1121120T1/el unknown
- 2019-03-04 US US16/291,800 patent/US20190192526A1/en not_active Abandoned
- 2019-05-02 IL IL266418A patent/IL266418A/en active IP Right Grant
- 2019-10-22 US US16/660,339 patent/US11052093B2/en active Active
-
2020
- 2020-10-29 IL IL278373A patent/IL278373B1/en unknown
- 2020-11-27 JP JP2020197115A patent/JP2021042243A/ja not_active Withdrawn
-
2021
- 2021-05-05 US US17/308,610 patent/US20210379076A1/en not_active Abandoned
- 2021-08-31 CY CY20211100771T patent/CY1124617T1/el unknown
-
2022
- 2022-11-11 JP JP2022181039A patent/JP2023011933A/ja active Pending
-
2024
- 2024-03-15 US US18/606,903 patent/US12161645B2/en active Active
- 2024-03-15 US US18/606,925 patent/US12168015B2/en active Active
- 2024-03-15 US US18/606,946 patent/US12168016B2/en active Active
- 2024-09-27 US US18/900,199 patent/US20250170138A1/en active Pending
-
2025
- 2025-10-28 IL IL324294A patent/IL324294A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018104450A5 (enExample) | ||
| JP2014516931A5 (enExample) | ||
| JP2014513084A5 (enExample) | ||
| RU2013150345A (ru) | Арил-или гетероарилзамещенные бензольные соединения | |
| JP2022023958A5 (enExample) | ||
| JP2023040165A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JPS58185553A (ja) | α−保護されたオキシイミノ−β−ケト−γ−ハロゲノ酪酸類 | |
| JP2016534148A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| MX2019000123A (es) | Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores. | |
| JP2020521766A5 (enExample) | ||
| JP2015516420A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| JP2015535834A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2018515491A5 (enExample) | ||
| JP2019527235A5 (enExample) | ||
| HRP20230233T1 (hr) | Inhibitori pirazola magl | |
| JP2014505723A5 (enExample) | ||
| JP2016514138A5 (enExample) | ||
| RU2017114005A (ru) | Производное изоксазола в качестве ингибитора мутантной изоцитратдегидрогеназы 1 |